SILEXION THERAPEUTICS CORP Operating Expenses
SILEXION THERAPEUTICS CORP (SLXN) reported Operating Expenses of $3.68 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- SILEXION THERAPEUTICS CORP operating expenses for the quarter ending 2026-06-30 was $3.68M, a 61.12% increase year-over-year.
- SILEXION THERAPEUTICS CORP operating expenses for the quarter ending 2026-03-31 was $2.75M, a 66.61% increase year-over-year.
- SILEXION THERAPEUTICS CORP operating expenses for the quarter ending 2025-12-31 was $4.41M, a 131.89% increase year-over-year.
- SILEXION THERAPEUTICS CORP operating expenses for the quarter ending 2025-09-30 was $3.29M, a 59.03% decline year-over-year.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.68M 10-Q · filed 2026-08-14 | $6.43M 10-Q · filed 2026-08-14 | $10.84M derived: sum of 3 quarters · filed 2026-08-14 | $14.13M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $2.75M S-1/A · filed 2026-08-10 | $7.16M derived: sum of 2 quarters · filed 2026-08-10 | $10.45M derived: sum of 3 quarters · filed 2026-08-10 | $12.73M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $4.41M derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-10 | $7.70M derived: sum of 2 quarters · filed 2026-08-10 | $9.98M derived: sum of 3 quarters · filed 2026-08-14 | $11.63M S-1/A · filed 2026-08-10 |
| 2025-09-30 | $3.29M 10-Q · filed 2025-11-12 | $5.58M derived: sum of 2 quarters · filed 2026-08-14 | $7.23M 10-Q · filed 2025-11-12 | $9.13M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $2.28M 10-Q · filed 2026-08-14 | $3.93M 10-Q · filed 2026-08-14 | $5.83M derived: sum of 3 quarters · filed 2026-08-14 | $13.87M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.65M S-1/A · filed 2026-08-10 | $3.55M derived: sum of 2 quarters · filed 2026-08-10 | $11.59M derived: sum of 3 quarters · filed 2026-08-10 | $12.97M derived: sum of 4 quarters · filed 2026-08-10 |
| 2024-12-31 | $1.90M derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-10 | $9.94M derived: sum of 2 quarters · filed 2026-08-10 | $11.32M derived: sum of 3 quarters · filed 2026-08-10 | $12.57M S-1/A · filed 2026-08-10 |
| 2024-09-30 | $8.04M 10-Q · filed 2025-11-12 | $9.42M derived: sum of 2 quarters · filed 2025-11-12 | $10.67M 10-Q · filed 2025-11-12 | $12.40M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.39M 10-Q · filed 2025-08-12 | $2.63M 10-Q · filed 2025-08-12 | $4.36M derived: sum of 3 quarters · filed 2025-08-20 | $5.09M derived: sum of 4 quarters · filed 2025-08-20 |
| 2024-03-31 | $1.25M 10-Q · filed 2025-05-13 | $2.98M derived: sum of 2 quarters · filed 2025-08-20 | $3.71M derived: sum of 3 quarters · filed 2025-08-20 | $5.12M derived: sum of 4 quarters · filed 2025-08-20 |
| 2023-12-31 | $1.73M derived: 8-K 12 month − 10-Q 9 month · filed 2025-08-20 | $2.46M derived: sum of 2 quarters · filed 2025-08-20 | $3.87M derived: sum of 3 quarters · filed 2025-08-20 | $4.68M 8-K · filed 2025-08-20 |
| 2023-09-30 | $731.00K 10-Q · filed 2024-11-14 | $2.15M derived: sum of 2 quarters · filed 2024-11-14 | $2.95M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $1.41M 10-Q · filed 2024-08-29 | $2.22M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |